Heparin Free Haemodialysis With Haemodialyzers "VIE" Versus "EVODIAL"

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-10-31

Study Completion Date

2011-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The adequate anti coagulation is an absolute necessity in order to avoid the extra-corporal circuit and haemodialyzer clotting and to perform an adequate renal replacement therapy during a haemodialysis session. In the cases of multiple coagulation defects having high haemorrhagic risk factors and the patients under anti-coagulation therapy, it is recommended to reduce the heparin doses or to do heparin free haemodialysis. Several strategies of low heparin or heparin free haemodialysis have been proposed till now, without a real success. The heparin coated polyacrylonitrile haemodialyser (EVODIAL) has been reported to have 90 % successful heparin-free haemodialysis sessions. On the other hand, the vitamin E coated polysulphone (VIE) has also been reported to have an anti oxidative and anti-thrombotic properties and a capacity to improve the haemorrheological factors of human blood, hence having a promising future to perform a successful haemodialysis session with less or without heparin. This randomised, multi-centric, cross-over and open study has been designed to compare non inferiority of the haemodialyzer VIE 2,1 versus EVODIAL2,2 with a risk alfa of 5% and an absolute accepted difference of 12 %.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

HepZero:Heparin Free Dialysis With Evodial

NCT01318486

Chronic Kidney Disease Patients Requiring Heparin Free Dialysis Treatments

COMPLETED NA

Reduction of Heparin Dose in Dialysis With Evodial System

NCT00781690

Chronic Kidney Failure

COMPLETED NA

Chronic Hemodialysis Without Systemic Heparinization : a Randomized Study

NCT00473109

Contra-Indication to the Use of Low Molecular Weight Heparin

COMPLETED PHASE3

Citrate Anticoagulation vs. Heparin-Coated Dialyzers

NCT00395824

Dialysis

COMPLETED PHASE3

Heparin-Free Chronic HemoDialysis Assessment

NCT06224140

End-Stage Renal Disease

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Adult Chronic Haemodialysis Patients Since at Least 3 Months

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

haemodialyzer EVODIAL-haemodialyzer VIE

Equal number of patients will start either with the haemodialyzer "VIE 2,1" or "EVODIAL 2,2" followed by a wash out period, before starting the other haemodialyzer.

Group Type OTHER

heparin free haemodialysis

Intervention Type OTHER

Comparison of two haemodialyzers "VIE 2,1" versus "EVODIAL 2,2" in a strategy of heparin-free haemodialysis (HFH).

haemodialyzer VIE-haemodialyzer Evodial

Equal number of patients will start either with the haemodialyzer "VIE 2,1" or "EVODIAL 2,2" followed by a wash out period, before starting the other haemodialyzer.

Group Type OTHER

heparin free haemodialysis

Intervention Type OTHER

Comparison of two haemodialyzers "VIE 2,1" versus "EVODIAL 2,2" in a strategy of heparin-free haemodialysis (HFH).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

heparin free haemodialysis

Comparison of two haemodialyzers "VIE 2,1" versus "EVODIAL 2,2" in a strategy of heparin-free haemodialysis (HFH).

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\-- Adult chronic haemodialysis patients since al least 3 months

* Two needles puncture of the fistula,
* Low molecular weight heparinization during haemodialysis sessions,
* Good fistula or central veinous catheter flow rate (blood pump flow rate ≥ 300 ml/min),
* Systolic blood pressure ≥ 110 mmHg (mean value of three last dialysis sessions.
* Patients capable to understand the design of the study and to follow the instructions
* Patients having the French social security system affiliation.

* C reactive protein \> 30 mg/L.
* Single needle puncture of the fistula
* Active documented haemorrhage,
* Haemoglobin \< 10 g/dl and/or need blood transfusion,
* Documented thrombophilia
* Patients waiting for renal graft
* Acute sepsis
* Fistula or catheter dysfunction
* Patients under anti-vitamine K
* Per dialytic hypotension requiring al least once a nurse intervention,
* Severe diseases (Dysglobulinemia, vascularitis, HIV…),
* Patients following another research protocol or have ended one less then one month before starting of this study.
* Pregnant or breast feeding patients,
* Minor patients or under law-protection

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No